<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244881</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02937</org_study_id>
    <secondary_id>05-160</secondary_id>
    <secondary_id>U01CA062490</secondary_id>
    <secondary_id>CDR0000445438</secondary_id>
    <nct_id>NCT00244881</nct_id>
    <nct_alias>NCT00215488</nct_alias>
  </id_info>
  <brief_title>A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)</brief_title>
  <official_title>A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial&#xD;
      is studying how well AZD2171 works in treating patients with refractory stage IV breast&#xD;
      cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluation of the fraction of patients with increased levels of circulating endothelial&#xD;
      cells after 3 weeks of treatment with AZD2171.&#xD;
&#xD;
      II. Estimation of the objective response rate (ORR = CR + PR) among patients with refractory&#xD;
      breast cancer receiving AZD2171.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Estimation of the response/stable disease rate (RSDR = CR + PR + SD). II. Characterization&#xD;
      of the toxicity associated with AZD2171 in this cohort of patients.&#xD;
&#xD;
      III. Analyses to correlate serial quantification of circulating endothelial cells and&#xD;
      circulating tumor cells with traditional clinical endpoints including RR and TTP.&#xD;
&#xD;
      IV. Develop pharmacodynamic measures of AZ2171 activity based on monocyte count and VEGFR-1&#xD;
      phosphorylation within monocytes.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, multicenter study.&#xD;
&#xD;
      Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 26 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fraction of Patients With Increased Levels of Circulating Endothelial Cells</measure>
    <time_frame>After 3 weeks of treatment</time_frame>
    <description>An exact 95% confidence interval (CI) will be calculated for the CEC response rate. With 26 patients, this CI will be no wider than 40% (e.g., if 13 of 26 patients respond, the CI is 30% to 70%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR = CR + PR) Classified According to RECIST Criteria</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>RECIST 1.0 Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response/Stable Disease Rate Defined as the Percentage of Patients Demonstrating CR + PR + SD</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cediranib maleate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
    <other_name>AZD2171</other_name>
    <other_name>Recentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cediranib maleate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed Breast Cancer, stage IV,&#xD;
             including:&#xD;
&#xD;
               -  &quot;Breast neoplasms malignant and unspecified (incl nipple)&quot;,&quot;Breast and nipple&#xD;
                  neoplasms malignant&quot;,&quot;Breast cancer stage IV&quot;,&quot;10006202&quot;&#xD;
&#xD;
               -  Breast neoplasms malignant and unspecified (incl nipple)&quot;,&quot;Breast and nipple&#xD;
                  neoplasms malignant&quot;,&quot;Breast cancer recurrent&quot;,&quot;10006198&quot;&#xD;
&#xD;
               -  &quot;Breast neoplasms malignant and unspecified (incl nipple)&quot;,&quot;Breast and nipple&#xD;
                  neoplasms malignant&quot;,&quot;Inflammatory carcinoma of breast stage IV&quot;,&quot;10021979&quot;&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=&#xD;
             20 mm with conventional techniques or as &gt;= 10 mm with spiral CT scan&#xD;
&#xD;
          -  Patients must have refractory breast cancer, defined as overt clinical tumor&#xD;
             progression on most recent treatment with either hormonal therapy, chemotherapy,&#xD;
             and/or trastuzumab therapy; patients with up to 3 prior chemotherapy regimens and with&#xD;
             any number of biological (hormonal, trastuzumab) regimens for metastatic breast cancer&#xD;
             will be eligible&#xD;
&#xD;
          -  Life expectancy of greater than 3 months as assessed by the patient's primary&#xD;
             oncologist&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mcL&#xD;
&#xD;
          -  Platelets &gt; 100,000/mcL&#xD;
&#xD;
          -  Hemoglobin &gt;= 8 g/dL&#xD;
&#xD;
          -  Prothrombin time &lt; institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN&#xD;
&#xD;
          -  AST(SGOT)/ALT(SGPT) =&lt; 2.5 Ã— ULN&#xD;
&#xD;
          -  Creatinine within normal institutional limits&#xD;
&#xD;
          -  Urinalysis with &lt; 1+ proteinuria&#xD;
&#xD;
          -  Troponin T or I within normal institutional limits&#xD;
&#xD;
          -  LVEF &gt;= 45%, as assessed by echocardiogram or nuclear medicine gated study, within 30&#xD;
             days prior to initiating protocol-based treatment&#xD;
&#xD;
          -  At present, the potential of AZD2171 for clinically significant drug interactions&#xD;
             involving the CYP isozymes is unknown; however, studies of the agent in rats indicated&#xD;
             possible suppression of CYP1A that may be of biological significance; eligibility of&#xD;
             patients receiving any medications or substances known to affect or with the potential&#xD;
             to affect the activity or PK of AZD2171 will be determined following review of their&#xD;
             case by the Principal Investigator.&#xD;
&#xD;
          -  AZD2171 has been shown to terminate fetal development in the rat, as expected for a&#xD;
             process dependent on VEGF signaling; for this reason, women of child-bearing potential&#xD;
             must have a negative pregnancy test prior to study entry; women of child-bearing&#xD;
             potential and men must agree to use adequate contraception (hormonal or barrier method&#xD;
             of birth control; abstinence) prior to study entry and for the duration of study&#xD;
             participation; should a woman become pregnant or suspect she is pregnant while&#xD;
             participating in this study, she should inform her treating physician immediately&#xD;
&#xD;
          -  No therapeutic anti-coagulation; the use of low dose warfarin (1-2 mg/day),&#xD;
             intermittent doses of TPA (2 mg x 1), or heparin flushes to prophylax against central&#xD;
             venous catheter-associated clots is acceptable&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy, radiotherapy, or major surgery within 4 weeks (6&#xD;
             weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have&#xD;
             not recovered from adverse events due to agents administered more than 4 weeks earlier&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents nor have participated&#xD;
             in an investigational trial within the past 30 days&#xD;
&#xD;
          -  Patients may not have been previously treated with an anti-angiogenesis agent&#xD;
&#xD;
          -  \Patients may not be receiving any medication that may markedly affect renal function&#xD;
             (e.g., vancomycin, amphotericin, pentamidine); these medications will also not be&#xD;
             permitted after the start of the study&#xD;
&#xD;
          -  Patients with known brain metastases should be excluded from this clinical trial&#xD;
             because of their poor prognosis and because they often develop progressive neurologic&#xD;
             dysfunction that would confound the evaluation of neurologic and other adverse events;&#xD;
             a head CT or MRI must be performed at baseline&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to AZD2171&#xD;
&#xD;
          -  Any contraindications/barrier to oral medication&#xD;
&#xD;
          -  EKG abnormalities of known clinical significance, such as prolonged QT (mean QTc &gt; 470&#xD;
             msec, with Bazett's correction, in screening electrocardiogram or history of familial&#xD;
             long QT syndrome); an EKG is required for study entry&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing&#xD;
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because AZD2171 is a VEGF inhibitor with&#xD;
             known abortifacient effects; because there is an unknown but potential risk for&#xD;
             adverse events in nursing infants secondary to treatment of the mother with AZD2171,&#xD;
             breastfeeding should be discontinued if the mother is treated with AZD2171&#xD;
&#xD;
          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of&#xD;
             the potential for pharmacokinetic interactions with AZD2171; appropriate studies will&#xD;
             be undertaken in patients receiving combination antiretroviral therapy when indicated&#xD;
&#xD;
          -  Patients at increased risk for compromised LVEF requiring concurrent use of drugs or&#xD;
             biologics with proarrythmic potential; these drugs are prohibited during studies with&#xD;
             AZD2171 (refer to Appendix J for a listing of these agents)&#xD;
&#xD;
          -  Patients with a New York Heart Association classification of III or IV are excluded&#xD;
             (NOTE: patients classified as class II are eligible if controlled on medication and&#xD;
             stable with increased monitoring)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Burstein</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <results_first_submitted>November 4, 2013</results_first_submitted>
  <results_first_submitted_qc>November 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2013</results_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at Dana-Farber/Harvard Cancer Center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Cediranib Maleate)</title>
          <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Cediranib Maleate)</title>
          <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fraction of Patients With Increased Levels of Circulating Endothelial Cells</title>
        <description>An exact 95% confidence interval (CI) will be calculated for the CEC response rate. With 26 patients, this CI will be no wider than 40% (e.g., if 13 of 26 patients respond, the CI is 30% to 70%).</description>
        <time_frame>After 3 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cediranib Maleate)</title>
            <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Patients With Increased Levels of Circulating Endothelial Cells</title>
          <description>An exact 95% confidence interval (CI) will be calculated for the CEC response rate. With 26 patients, this CI will be no wider than 40% (e.g., if 13 of 26 patients respond, the CI is 30% to 70%).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR = CR + PR) Classified According to RECIST Criteria</title>
        <description>RECIST 1.0 Criteria</description>
        <time_frame>Up to 7 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cediranib Maleate)</title>
            <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR = CR + PR) Classified According to RECIST Criteria</title>
          <description>RECIST 1.0 Criteria</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="1" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response/Stable Disease Rate Defined as the Percentage of Patients Demonstrating CR + PR + SD</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cediranib Maleate)</title>
            <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Response/Stable Disease Rate Defined as the Percentage of Patients Demonstrating CR + PR + SD</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Cediranib Maleate)</title>
          <description>Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left Ventricular Systolic Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gallbladder Abnormality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>LFT Abnormalities</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>LV systolic dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Esophagitis/Mucositis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Harold Burstein</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-3800</phone>
      <email>hburstein@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

